"Our founding team has over 20 years of research experience in the field of apoptosis and accumulated deep expertise on the BCL-2 target," Dajun Yang, MD, PhD,chairman and chief executive officer of Ascentage Pharma, added in the news release. 1 "This approval for lisaftoclax is a culmination of their dedicated research and a major milestone in our never-ending journey of innovation, further solidifying our leadership in the hematology field. As a proprietary novel drug developed through global innovation, lisaftoclax is a testament to our strength in drug development, bringing much needed change to the global landscape for BCL-2 inhibitors. Moving forward, Ascentage Pharma will remain steadfastly committed to its mission of addressing unmet clinical needs in China and around the world and aspire to bring more innovative therapeutics to more patients globally."